CNS (central nervous system) trials are some of the most complex–and most meaningful–studies in clinical research today. A recent Society for Clinical Research Sites (SCRS) SCRS Talks episode featuring Tekton’s Jeffrey Zucker and Brandon Lenfest explored the realities of conducting CNS trials—from patient identification to caregiver impact.
In this article, we revisit the most compelling moments from that discussion and expand on what they reveal about running successful CNS trials today, with perspective from Tekton’s physician-led model and site experience.
It Starts with Physicians Who Know Their Patients
One of the biggest differentiators in CNS trials is how patients are identified. Unlike other therapeutic areas, eligibility isn’t always obvious from a chart alone.
“These physicians already know their patients… they have people top of mind who may qualify.”
This is where Tekton’s physician-led model becomes critical. When investigators are actively treating patients, they’re not just reviewing criteria–they’re recognizing real people who may benefit from participation. That connection can accelerate enrollment while ensuring a more thoughtful, patient-centered approach.
Reducing the Burden on Physicians
CNS trials are operationally demanding. Between complex protocols, extended visit schedules, and detailed assessments, the workload can quickly become overwhelming.
That’s why infrastructure matters.
“We take that burden off… so the PI can focus on safety, efficacy, and protocol.”
By centralizing operational support, Tekton enables investigators to stay focused on what matters most: delivering high-quality care and ensuring study integrity. It’s a model designed not just for efficiency–but for better outcomes.
Measuring Progress Isn’t Always Straightforward
Unlike other conditions, CNS disorders don’t always come with clear-cut biomarkers.
As Brandon Lenfest put it:
“We can’t just draw blood to see if your depression went away.”
This makes endpoints more subjective–and elevates the importance of consistency, training, and patient engagement throughout the study. It also underscores why experienced investigators and well-supported site teams are essential in this space.
The Challenge of Placebo Response
One of the most well-known hurdles in CNS trials is placebo response–and its impact can be significant.
“Placebo response can kill studies.”
Managing this requires careful protocol design, strong site execution, and thoughtful patient communication. It’s a balancing act between maintaining scientific rigor and providing empathetic care–something CNS sites navigate every day.
Never Forget the Caregiver
Perhaps the most powerful reminder from the conversation was the human side of CNS conditions–especially for caregivers.
“Caregivers are devastated… they’ve seen someone go from fully functional to not.”
Behind every patient is often a support system navigating that journey alongside them. Successful CNS trials recognize this reality, incorporating caregivers into the process and supporting them as key partners in care.
Moving CNS Research Forward–Together
CNS trials are complex, nuanced, and deeply human. They require more than just infrastructure–they require empathy, experience, and a model built around real patient relationships.
Conversations like this highlight an important truth: advancing neuroscience research isn’t just about protocols and timelines. It’s about people–patients, caregivers, and physicians–working together to move science forward.
At Tekton, that’s what “Together in Research” truly means.